Advertisement
Advertisement
HELP
H
Cybin Inc. Common Stock
5.31
USDSponsored
-0.03
-0.56%
May 08, 16:00 UTC -4
Closed
Pre-Market
5.32
+0.01
+0.19%
HELP Earnings Reports
Positive Surprise Ratio
HELP beat 0 of 2 last estimates.
0%
Next Report
Date of Next Report
Jun 29, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.91
Implied change from Q3 26 (Revenue/ EPS)
--
/-34.53%
Implied change from Q4 25 (Revenue/ EPS)
--
/-37.67%
Cybin Inc. Common Stock earnings per share and revenue
On Feb 13, 2026, HELP reported earnings of -1.39 USD per share (EPS) for Q3 26, missing the estimate of -0.68 USD, resulting in a -103.59% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.87% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of -0.91 USD, with revenue projected to reach -- USD, implying an decrease of -34.53% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Cybin Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Cybin Inc. Common Stock reported EPS of -$1.39, missing estimates by -103.59%, and revenue of $0.00, 0% as expectations.
How did the market react to Cybin Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 2.87%, changed from $5.92 before the earnings release to $6.09 the day after.
When is Cybin Inc. Common Stock expected to report next?
The next earning report is scheduled for Jun 29, 2026.
What are the forecasts for Cybin Inc. Common Stock's next earnings report?
Based on 5
analysts, Cybin Inc. Common Stock is expected to report EPS of -$0.91 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement